MedTrace Logo

Acute Local Metabolomic Alterations in Blood and Muscle Tissue in Intermittent Claudication

NCT05111379 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-05-25

No results posted yet for this study

Summary

The most common clinical presentation of lower extremity arterial disease is intermittent claudication. Current understanding of the pathophysiology of intermittent claudication, as well as its treatment options are limited. The progression of the disease may lead to lower limb amputation, which is devastating for patients' quality of life and is a huge socio-economic burden to society.

Current study allows to determine the acute local metabolomic alterations in the ischaemic limb of the patient with intermittent claudication, and investigate the associations between the metabolomic alterations and the patient's maximal walking distance. This provides potentially valuable insight into the pathophysiology of this disease, and helps lay the groundwork for identifying potential novel targets for instituting more effective therapies for this high-risk population.

Conditions

  • Peripheral Arterial Occlusive Disease Fontaine Stage IIa

Sponsors & Collaborators

  • Tartu University Hospital

    collaborator OTHER

  • Estonian Science Foundation

    collaborator OTHER_GOV

  • University of Tartu

    lead OTHER

Principal Investigators

  • Jaak Kals, MD, PhD · University of Tartu

  • Kaido Paapstel, MD, PhD · University of Tartu

  • Kalle Kilk, MD, PhD · University of Tartu

  • Holger Post, MD · University of Tartu

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-28
Primary Completion
2023-08-31
Completion
2025-08-31

Countries

  • Estonia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05111379 on ClinicalTrials.gov